Search Within

Michael Andrew Postow

Formats
  1. Journal Article (196)
  2. Meeting Abstract (138)
  3. Review (10)
  4. Editorial (9)
  5. Book Section (4)
  6. Guidelines (4)
  7. Research Letter (4)
  8. Miscellaneous (2)
  9. Book Whole (1)
  10. Correspondence (1)
Groups
  1. Department of Medicine (369)
  2. Melanoma Disease Management Team (369)
  3. Melanoma and Immunotherapeutics Service (369)
  4. Solid Tumor Oncology Division (369)
  5. GSK Faculty (178)
  6. Hematologic Malignancies, Division of (105)

More Groups

People
  1. Jedd Wolchok (158)
  2. Margaret Callahan (96)
  3. Katherine Panageas (66)
  4. Alexander Shoushtari (64)
  5. Paul Chapman (55)
  6. Parisa Momtaz (37)

More People

Years
  1. 2025 (23)
  2. 2024 (19)
  3. 2023 (23)
  4. 2022 (23)
  5. 2021 (27)
  6. 2020 (30)

More Years

Publications
  1. Journal of Clinical Oncology (92)
  2. Journal for ImmunoTherapy of Cancer (34)
  3. Clinical Cancer Research (16)
  4. Annals of Oncology (13)
  5. International Journal of Radiation Oncology, Biology, Physics (12)
  6. The Oncologist (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (94)
  2. Biomed Central Ltd (43)
  3. Elsevier Inc. (32)
  4. Oxford University Press (32)
  5. American Association for Cancer Research (24)
  6. Wiley Blackwell (21)

More Publishers

Results (369)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma
    Meeting Abstract

    Jameson-Lee, M.; Ott, P. A.; Luke, J. J.; Postow, M. A.; Poklepovic, A. S.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma
    Meeting Abstract

    Amaria, R. N.; Postow, M. A.; Tetzlaff, M. T.; Ross, M. I.; Glitza, I. C.; McQuade, J. L.; Wong, M. K. K.; Gershenwald, J. E.; Goepfert, R.; Keung, E. Z. Y.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors
    Meeting Abstract

    Sarfaty, M.; Desjardins, C. A.; Giardina, P.; Bardhan, K.; Pandian, S.; Halley, K.; Halvorsen, E. M.; Callahan, M. K.; Postow, M. A.; Lee, C. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB)
    Meeting Abstract

    Loo, K.; Goldman, D. A.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • KEYMAKER-U02: Investigational agents with or without pembrolizumab or pembrolizumab alone in melanoma
    Meeting Abstract

    Long, G. V.; Dummer, R.; Pavlick, A. C.; Postow, M. A.; Ribas, A.; Robert, C.; Scolyer, R. A.; Taube, J. M.; Tetzlaff, M.; Su, S. C.; more...
    Asia-Pacific Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
    Journal Article

    Tawbi, H. A.; Forsyth, P. A.; Hodi, F. S.; Lao, C. D.; Moschos, S. J.; Hamid, O.; Atkins, M. B.; Lewis, K.; Thomas, R. P.; Glaspy, J. A.; more...
    Neuro-Oncology (2021)

    Fulltext@MSK | Save
  • Dermatologic infections in cancer patients treated with checkpoint inhibitors
    Journal Article

    Do, M. H.; Barrios, D. M.; Phillips, G. S.; Postow, M. A.; Warner, A. B.; Rosenberg, J. E.; Noor, S. J.; Markova, A.; Lacouture, M. E.
    Journal of the American Academy of Dermatology (2021)

    Fulltext@MSK | Save
  • Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Journal Article

    Chapman, P. B.; Jayaprakasam, V. S.; Panageas, K. S.; Callahan, M.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; Betof Warner, A.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
    Meeting Abstract

    Margolin, K. A.; Korn, R.; Farwell, M.; Postow, M. A.; Hays, D.; Wilson, I. A.; Le, W. H.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
    Meeting Abstract

    Dummer, R.; Long, G. V.; Pavlick, A. C.; Postow, M. A.; Ribas, A.; Robert, C.; Scolyer, R. A.; Taube, J. M.; Tetzlaff, M.; Su, S. C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save